Share Prices & Company Research

Stockbroking

GlaxoSmithKline

Current Price 1525.60p Bid 1519.80p Ask 1525.60p Change 0.32%
Last Updated: 18/09/2020 23:18. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

UK-based GlaxoSmithKline is one of the world's leading pharmaceutical research companies. The company was created out of the merger between GlaxoWellcome and SmithKline Beecham in 2000.

Financial Highlights Year Ended 31/12/2019

Revenue
£33,754.00m
Operating Profit/Loss
£6,961.00m
Dividend yield (%)
4.50
Total dividend for year
80.0000p
Dividend cover
1.55
P/E Ratio
14.40

Key Personnel

Ms Emma Walmsley
Chief Executive Officer
Mr Iain Mackay
Chief Financial Officer
Mr Hal Barron
Chief Scientific Officer
Dr Jesse Goodman
Independent Non-Executive Director
Dr Laurie Glimcher
Independent Non-Executive Director
Mr Urs Rohner
Independent Non-Executive Director
Ms Judy Lewent
Independent Non-Executive Director
Ms Lynn Elsenhans
Independent Non-Executive Director
Ms Vivienne Cox
Independent Non-Executive Director
Mr Jonathan Symonds
Non-Executive Chairman
Mr Charles Bancroft
Non-Executive Director
Mr Manvinder Singh Banga
Senior Independent Non-Executive Director

Stock Details

EPIC
GSK
ISIN
GB0009252882
Shares in Issue
5,017.36m
Market cap
£76,544.90m

Analyst Views (1)

Strong Buy
 
0%
Buy
 
0%
Hold
 
0%
Sell
 
100.00%
Strong Sell
 
0%
This information is provided by Web Financial Group (UK) Limited. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
1,525.60p
Bid Price
1,519.80p
Ask Price
1,525.60p
Volume
11,938,918
Change Today
4.80p
% Change Today
0.32%
Open
1,516.60p
Previous Close
1,525.60p
Intraday High
1,533.00p
Intraday Low
1,511.80p
52 Week High
1,846.00p
52 Week Low
1,374.60p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

News

EU agrees to purchase Sanofi/GSK Covid-19 vaccine 18/09/2020 11:01:39 GSK, Sanofi start trials of Covid-19 vaccine 03/09/2020 07:03:39 GSK receives FDA approval for BLENREP 06/08/2020 08:02:25 Sanofi under investigation on charges including manslaughter 03/08/2020 11:26:15 GSK and Sanofi in talks to supply 300m vaccine doses to EU 03/08/2020 07:43:48 Washington to support GSK and Sanofi Covid-19 vaccine with $2.1bn 31/07/2020 12:35:06 GlaxoSmithKline stands by full-year EPS guidance but with a caveat 29/07/2020 12:30:34 GlaxoSmithKline stands by full-year EPS guidance but with a caveat 29/07/2020 12:30:34 Iran launches missiles at mock US Navy ship raising tensions 29/07/2020 08:49:13 Sanofi and GSK to provide UK with 60m doses of Covid-19 vaccine 29/07/2020 07:31:32 Glaxo to invest £130m in CureVac infectious disease collaboration 20/07/2020 06:56:25 GlaxoSmithKline myeloma treatment gets nod from FDA committee 15/07/2020 07:30:49 GSK partners with Canada's Medicago to develop plant-based Covid-19 vaccine 07/07/2020 16:59:51 GlaxoSmithKline clears regulatory hurdle in Japan for 'Duvroq' 29/06/2020 08:28:59 GSK to produce 1bn doses of vaccine boosters 28/05/2020 11:06:18 GlaxoSmithKline hails HIV treatment breakthrough 18/05/2020 07:40:42 GlaxoSmithKline divests of holding in Hindustan Unilever 07/05/2020 09:28:55 GlaxoSmithKline gets FDA nod for latest 'Zejula' application 30/04/2020 07:37:36 GlaxoSmithKline Q1 sales jump; full-year guidance reaffirmed 29/04/2020 12:13:45

Income Statement

Year End Date
31 Dec 2019
31 Dec 2018
 
£ (M)
£ (M)
Continuing Operations
Revenue
33,754.00
30,821.00
Operating Profit/Loss
6,961.00
5,483.00
Net Interest
-814.00
-717.00
Pre-Tax Profit
6,221.00
4,800.00
Profit After Tax from continuing operations
5,268.00
4,046.00
Discontinued Operations
Profit After Tax
n/a
n/a
Profit/Loss for the Year
5,268.00
4,046.00
Attributable to:
Equity Holders of Parent Company
5,268.00
4,046.00
Minority Interests
n/a
423.00
Total Dividend Paid
80.0000p
80.0000p
Retained Profit/(Loss) for the Financial Year
n/a
n/a

Earnings per Share

Year End Date
31 Dec 2019
31 Dec 2018
Basic
93.90p
73.70p
Diluted
92.60p
72.90p
Adjusted
123.90p
119.40p
Dividend per Share
80.0000p
80.0000p

Assets

Year End Date
31 Dec 2019
31 Dec 2018
 
£ (M)
£ (M)
Non-Current Assets
Property, Plant & Equipment
10,348.00
11,058.00
Intangible Assets
41,517.00
22,991.00
Investment Properties
n/a
n/a
Investments
2,151.00
1,558.00
Other Financial Assets
103.00
69.00
Other Non-Current Assets
6,082.00
5,463.00
Current Assets
Inventories
5,947.00
5,476.00
Trade & Other Receivables
7,464.00
6,652.00
Cash at Bank & In Hand
4,707.00
3,874.00
Current Asset Investments
n/a
84.00
Other Current Assets
1,373.00
925.00
Other Assets
n/a
n/a
Total Assets
79,692.00
58,066.00

Liabilities

Year End Date
31 Dec 2019
31 Dec 2018
 
£ (M)
£ (M)
Current Liabilities
Borrowings
6,918.00
5,793.00
Other Current Liabilities
17,132.00
16,698.00
Total Current Liabilities
24,050.00
22,491.00
Non-Current Liabilities
Borrowings
23,590.00
20,271.00
Provisions
4,480.00
1,847.00
Other Non-Current Liabilities
9,215.00
9,785.00
Total Non-Current Liabilities
37,285.00
31,903.00
Other Liabilities
n/a
n/a
Total Liabilities
61,335.00
54,394.00

Net Assets

Year End Date
31 Dec 2019
31 Dec 2018
 
£ (M)
£ (M)
Net Assets
18,357.00
3,672.00

Capital & Reserves

Year End Date
31 Dec 2019
31 Dec 2018
 
£ (M)
£ (M)
Share Capital
1,346.00
1,345.00
Share Premium Account
3,174.00
3,091.00
Other Reserves
2,355.00
2,061.00
Retained Earnings
5,109.00
-2,137.00
Shareholders Funds
11,984.00
4,360.00
Minority Interests/Other Equity
6,373.00
-688.00
Total Equity
18,357.00
3,672.00

Dividend History

Type
Ex-Dividend Date
Payment Date
Payment
Q2
13 Aug 2020
08 Oct 2020
19.00p
Q1
14 May 2020
09 Jul 2020
19.00p
Q4
20 Feb 2020
09 Apr 2020
23.00p
Q3
14 Nov 2019
09 Jan 2020
19.00p
Q2
08 Aug 2019
10 Oct 2019
19.00p
Q1
16 May 2019
11 Jul 2019
19.00p
Q4
21 Feb 2019
11 Apr 2019
23.00p
Q3
15 Nov 2018
10 Jan 2019
19.00p
Q2
09 Aug 2018
11 Oct 2018
19.00p
Q1
10 May 2018
12 Jul 2018
19.00p
Q4
22 Feb 2018
12 Apr 2018
23.00p
Q3
09 Nov 2017
11 Jan 2018
19.00p
Q2
10 Aug 2017
12 Oct 2017
19.00p
Q1
11 May 2017
13 Jul 2017
19.00p
Q4
23 Feb 2017
13 Apr 2017
23.00p
Q3
03 Nov 2016
12 Jan 2017
19.00p
Q2
11 Aug 2016
13 Oct 2016
19.00p
Q1
12 May 2016
14 Jul 2016
19.00p
Q4
18 Feb 2016
14 Apr 2016
23.00p
Q4
18 Feb 2016
14 Apr 2016
23.00p
Q3
12 Nov 2015
14 Jan 2016
19.00p
Q2
13 Aug 2015
01 Oct 2015
19.00p
Q1
14 May 2015
09 Jul 2015
19.00p

Dividend Metrics

Year End Date
31 Dec 2019
31 Dec 2018
Dividend growth
n/a%
n/a%
Dividend yield
4.50%
5.40%
Dividend cover
1.55
1.49
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.